Meyka AI API is live for developers.Start building.
Advertisement
Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. (HALO) Stock Overview

Explore Halozyme Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

HALO●NASDAQ
HealthcareBiotechnology
$71.15
$1.53(2.20%)
U.S. Market opens in 7h 42m
Advertisement

Halozyme Therapeutics, Inc. (HALO)

Meyka AI Score

Z

Key Financials

Market Cap8.4B
P/E Ratio24.58
EPS (TTM)$4.62
ROE1.26%
Fundamental Analysis

AI Price Forecasts

1 Month$76.37
3 Months$86.74
1 Year Target$80.56

HALO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Halozyme Therapeutics, Inc. (HALO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 57.51, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $80.56.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 24.58 and a market capitalization of 8.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.20%
5-Day Change
2.61%
1-Month Change
4.14%
3-Month Change
14.68%
6-Month Change
4.005%
Year-to-Date (YTD) Change
5.72%
1-Year Change
32.004%
3-Year Change
104.22%
5-Year Change
56.20%
All-Time (Max) Change
1574.12%

Contact Information

https://www.halozyme.com
858 794 8889
11388 Sorrento Valley Road, San Diego, CA, 92121

Company Facts

3,500 Employees
IPO DateMar 16, 2004
CountryUS
Actively Trading

Frequently Asked Questions